Table 2.

Tissue Sampling, Molecular Success Rate, and Material Allocation

	N (Total)	N (Subset)	Description
Sampling Approach
Biopsy and FNA/cytology total	61	…
Tumor present in both	…	40
Tumor in tissue biopsy only	…	15	Considering only the cell block of the FNA/cytology component
Tumor present in FNA/cytology only	…	0
No tumor present in entire sampling	…	6	Considering only the cell block of the FNA/cytology component
Tumor present in any combination	…	55 (90.2%)	Of all cases with biopsy and FNA/cytology (n = 61)
Biopsy only total	12
Tumor present	…	11 (91.7%)	Of cases with only biopsy (n = 12)
FNA/cytology only total	2
Tumor present	…	1 (50%)	Of cases with only FNA/cytology (n = 2)
Total cases	75	…
Molecular Success
Overall tumor present	67 (89.3%)	…	Of cases submitted (n = 75)
Successful molecular testing	…	60 (89.5%)	Of cases with tumor present (n = 67)
Overall molecular success	60 (80%)	…	Of all submitted cases (n = 75)
Unsuccessful for molecular testing	7 (10.4%)	…	Of cases with tumor present (n = 67)
Tumor too scant	…	5 (71.4%)	Of cases unsuccessful for testing (n = 7)
Patient died before testing (testing canceled)	…	1 (14.3%)	Of cases unsuccessful for testing (n = 7)
Small cell morphology (resistance; testing canceled)	…	1 (14.3%)	Of cases unsuccessful for testing (n = 7)
Material Allocation
Total successful molecular testing	60	…
No. using >1 block	20 (33.3%)	…	Of cases with successful molecular testing (n = 60)
No. using combined biopsy and FNA/cytology material	…	3 (15%)	Of cases using >1 block (n = 20)
No. with FNA/cytology chosen over biopsy	12 (30%)	…	Of cases with tumor in biopsy and FNA/cytology (n = 40)
No. using a single block	28 (46.7%)	…	Of cases with successful molecular testing (n = 60)

Abbreviation: FNA, fine-needle aspirate.